252 related articles for article (PubMed ID: 28974245)
1. Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency.
Dósa E; Heltai K; Radovits T; Molnár G; Kapocsi J; Merkely B; Fu R; Doolittle ND; Tóth GB; Urdang Z; Neuwelt EA
Fluids Barriers CNS; 2017 Oct; 14(1):26. PubMed ID: 28974245
[TBL] [Abstract][Full Text] [Related]
2. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models.
Dickey DT; Muldoon LL; Doolittle ND; Peterson DR; Kraemer DF; Neuwelt EA
Cancer Chemother Pharmacol; 2008 Jul; 62(2):235-41. PubMed ID: 17909806
[TBL] [Abstract][Full Text] [Related]
3. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.
Muldoon LL; Wu YJ; Pagel MA; Neuwelt EA
J Neurooncol; 2015 Feb; 121(3):433-40. PubMed ID: 25411097
[TBL] [Abstract][Full Text] [Related]
5. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy.
Riga MG; Chelis L; Kakolyris S; Papadopoulos S; Stathakidou S; Chamalidou E; Xenidis N; Amarantidis K; Dimopoulos P; Danielides V
Am J Clin Oncol; 2013 Feb; 36(1):1-6. PubMed ID: 22134515
[TBL] [Abstract][Full Text] [Related]
6. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
7. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial.
Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D
Heart Lung Circ; 2005 Dec; 14(4):245-51. PubMed ID: 16360994
[TBL] [Abstract][Full Text] [Related]
8. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?
Erturk M; Uslu N; Gorgulu S; Akbay E; Kurtulus G; Akturk IF; Akgul O; Surgit O; Uzun F; Gul M; Isiksacan N; Yildirim A
Coron Artery Dis; 2014 Mar; 25(2):111-7. PubMed ID: 24365793
[TBL] [Abstract][Full Text] [Related]
9. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.
Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Feb; 312(2):424-31. PubMed ID: 15496615
[TBL] [Abstract][Full Text] [Related]
10. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
[TBL] [Abstract][Full Text] [Related]
11. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
12. Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial.
Orgel E; Knight KR; Chi YY; Malvar J; Rushing T; Mena V; Eisenberg LS; Rassekh SR; Ross CJD; Scott EN; Neely M; Neuwelt EA; Muldoon LL; Freyer DR
Clin Cancer Res; 2023 Jul; 29(13):2410-2418. PubMed ID: 37134194
[TBL] [Abstract][Full Text] [Related]
13. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
[TBL] [Abstract][Full Text] [Related]
14. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
16. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine improves renal hemodynamics in rats with cisplatin-induced nephrotoxicity.
Abdelrahman AM; Al Salam S; AlMahruqi AS; Al husseni IS; Mansour MA; Ali BH
J Appl Toxicol; 2010 Jan; 30(1):15-21. PubMed ID: 19681060
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials.
Hu J; Zhang Q; Ren X; Sun Z; Quan Q
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):594-9. PubMed ID: 25732608
[TBL] [Abstract][Full Text] [Related]
20. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency.
Atkuri KR; Mantovani JJ; Herzenberg LA; Herzenberg LA
Curr Opin Pharmacol; 2007 Aug; 7(4):355-9. PubMed ID: 17602868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
